Pharmaron Beijing (China) Today
| 300759 Stock | 28.38 0.26 0.91% |
Performance12 of 100
| Odds Of DistressLess than 9
|
Pharmaron Beijing is trading at 28.38 as of the 22nd of November 2024, a 0.91 percent decrease since the beginning of the trading day. The stock's open price was 28.64. Pharmaron Beijing has less than a 9 % chance of experiencing financial distress in the next few years and had a good performance during the last 90 days. Equity ratings for Pharmaron Beijing Co are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 26th of May 2024 and ending today, the 22nd of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | Category Healthcare | Classification Health Care |
Pharmaron Beijing is entity of China. It is traded as Stock on SHE exchange. The company has 1.49 B outstanding shares. More on Pharmaron Beijing Co
Moving together with Pharmaron Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Pharmaron Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Pharmaron Beijing's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Pharmaron Beijing or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| Chairman CEO | Boliang Lou | ||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | ||||
Pharmaron Beijing's financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Pharmaron Beijing's success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit. | |||||
Debt LevelsPharmaron Beijing can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Pharmaron Beijing's financial leverage. It provides some insight into what part of Pharmaron Beijing's total assets is financed by creditors.
| |||||
Pharmaron Beijing Co (300759) is traded on Shenzhen Stock Exchange in China and employs 20,295 people. Pharmaron Beijing is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Large-Cap' category with a current market capitalization of 49.1 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Pharmaron Beijing's market, we take the total number of its shares issued and multiply it by Pharmaron Beijing's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Pharmaron Beijing operates under Biotechnology sector and is part of Health Care industry. The entity has 1.49 B outstanding shares.
Pharmaron Beijing generates positive cash flow from operations, but has no cash available
Check Pharmaron Beijing Probability Of Bankruptcy
Ownership AllocationPharmaron Beijing has a total of 1.49 Billion outstanding shares. Pharmaron Beijing has significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Note that regardless of who owns the company, if the true value of the entity is less than the market is willing to pay for it, you may not be able to generate positive returns over time.
Check Pharmaron Ownership Details
Pharmaron Beijing Risk Profiles
Although Pharmaron Beijing's alpha and beta are two of the key measurements used to evaluate Pharmaron Beijing's performance over the market, the standard measures of volatility play an important role as well.
| Mean Deviation | 3.25 | |||
| Semi Deviation | 3.6 | |||
| Standard Deviation | 5.12 | |||
| Variance | 26.17 |
Pharmaron Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in Pharmaron Beijing without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Companies Directory Now
Companies DirectoryEvaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals |
| All Next | Launch Module |
Pharmaron Beijing Corporate Management
Elected by the shareholders, the Pharmaron Beijing's board of directors comprises two types of representatives: Pharmaron Beijing inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Pharmaron. The board's role is to monitor Pharmaron Beijing's management team and ensure that shareholders' interests are well served. Pharmaron Beijing's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Pharmaron Beijing's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Jingqi Huang | Senior Pharmacology | Profile | |
| Jane Zhang | Chief Services | Profile | |
| Celina Zhong | Senior Resources | Profile | |
| Mandy Xu | Senior DMPK | Profile | |
| Connie Sun | Senior Development | Profile | |
| Stephen Lewinton | Senior Operations | Profile | |
| Sid Bhoopathy | Senior CGT | Profile |
Other Information on Investing in Pharmaron Stock
Pharmaron Beijing financial ratios help investors to determine whether Pharmaron Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Pharmaron with respect to the benefits of owning Pharmaron Beijing security.